S. J. Coggins, M. Govendir, J. M. Norris, R. Malik, E. J. Hall, M. F. Thompson, B. Kimble
{"title":"22例猫感染性腹膜炎静脉注射瑞德西韦后，GS-441524在6只猫体内的药代动力学及药物监测结果（2021-2024）","authors":"S. J. Coggins, M. Govendir, J. M. Norris, R. Malik, E. J. Hall, M. F. Thompson, B. Kimble","doi":"10.1111/jsap.13849","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>This study aimed to: (1) characterise the pharmacokinetics of GS-441524 following intravenous (iv) administration of 15 mg/kg remdesivir (RDV) in client-owned cats with feline infectious peritonitis (FIP); (2) document plasma protein binding of GS-441524 in cats; (3) determine whether trough GS-441524 plasma concentrations predict ‘simple remission’ or survival to 18 months; (4) measure GS-441524 concentration in effusions relative to plasma; and (5) qualitatively assess excretion of GS-441524 in urine.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>Six cats with FIP were administered 15 mg/kg iv RDV. Serial plasma GS-441524 concentrations were measured using high-performance liquid chromatography (HPLC). Twenty-two cats with FIP had trough plasma concentrations monitored over a 12-week treatment period. Simultaneous effusion and plasma GS-441524 concentrations were compared, and urine was assessed for GS-441524 excretion.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The mean peak plasma concentration of GS-441524 (<i>C</i><sub>max</sub>) after a single 15 mg/kg iv dose of RDV was 2632 ng/mL (SD 862); time to reach <i>C</i><sub>max</sub> (<i>T</i><sub>max</sub>) was 1 hour (SD 0); and elimination half-life (<i>t</i><sub>1/2</sub>) was 5.14 hours (SD 0.81). GS-441524 was present in effusions (<i>n</i> = 3 cats) and eliminated in urine following treatment (<i>n</i> = 6 cats). Assessment of the predictive relationship between median GS<sub>TC</sub> and achieving ‘simple remission’ failed to demonstrate a significant correlation.</p>\n </section>\n \n <section>\n \n <h3> Clinical Significance</h3>\n \n <p>This study supports the use of RDV and GS-441524 for FIP treatment and suggests that population pharmacokinetic modelling is required to better explore the utility of therapeutic drug monitoring of GS-441524.</p>\n </section>\n </div>","PeriodicalId":17062,"journal":{"name":"Journal of Small Animal Practice","volume":"66 7","pages":"495-506"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jsap.13849","citationCount":"0","resultStr":"{\"title\":\"Pharmacokinetics of GS-441524 following intravenous remdesivir in six cats and results of therapeutic drug monitoring during treatment of feline infectious peritonitis: 22 cases (2021–2024)\",\"authors\":\"S. J. Coggins, M. Govendir, J. M. Norris, R. Malik, E. J. Hall, M. F. Thompson, B. Kimble\",\"doi\":\"10.1111/jsap.13849\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>This study aimed to: (1) characterise the pharmacokinetics of GS-441524 following intravenous (iv) administration of 15 mg/kg remdesivir (RDV) in client-owned cats with feline infectious peritonitis (FIP); (2) document plasma protein binding of GS-441524 in cats; (3) determine whether trough GS-441524 plasma concentrations predict ‘simple remission’ or survival to 18 months; (4) measure GS-441524 concentration in effusions relative to plasma; and (5) qualitatively assess excretion of GS-441524 in urine.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Materials and Methods</h3>\\n \\n <p>Six cats with FIP were administered 15 mg/kg iv RDV. Serial plasma GS-441524 concentrations were measured using high-performance liquid chromatography (HPLC). Twenty-two cats with FIP had trough plasma concentrations monitored over a 12-week treatment period. Simultaneous effusion and plasma GS-441524 concentrations were compared, and urine was assessed for GS-441524 excretion.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The mean peak plasma concentration of GS-441524 (<i>C</i><sub>max</sub>) after a single 15 mg/kg iv dose of RDV was 2632 ng/mL (SD 862); time to reach <i>C</i><sub>max</sub> (<i>T</i><sub>max</sub>) was 1 hour (SD 0); and elimination half-life (<i>t</i><sub>1/2</sub>) was 5.14 hours (SD 0.81). GS-441524 was present in effusions (<i>n</i> = 3 cats) and eliminated in urine following treatment (<i>n</i> = 6 cats). Assessment of the predictive relationship between median GS<sub>TC</sub> and achieving ‘simple remission’ failed to demonstrate a significant correlation.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Clinical Significance</h3>\\n \\n <p>This study supports the use of RDV and GS-441524 for FIP treatment and suggests that population pharmacokinetic modelling is required to better explore the utility of therapeutic drug monitoring of GS-441524.</p>\\n </section>\\n </div>\",\"PeriodicalId\":17062,\"journal\":{\"name\":\"Journal of Small Animal Practice\",\"volume\":\"66 7\",\"pages\":\"495-506\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jsap.13849\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Small Animal Practice\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jsap.13849\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"VETERINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Small Animal Practice","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jsap.13849","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
摘要
目的：本研究旨在：(1)在患有猫传染性腹膜炎（FIP）的客户猫体内，静脉给药15mg /kg瑞德西韦（RDV）后，研究GS-441524的药代动力学特征；(2)记录了GS-441524在猫体内的血浆蛋白结合；(3)确定GS-441524血浆浓度是否预测“单纯缓解”或生存至18个月；(4)测定积液中GS-441524相对于血浆的浓度；(5)定性评估GS-441524在尿中的排泄情况。材料与方法：6只FIP猫给予15 mg/kg iv RDV。采用高效液相色谱法测定GS-441524系列血浆浓度。在12周的治疗期间，对22只FIP猫进行了低谷血浆浓度监测。同时比较积液和血浆GS-441524浓度，并评估尿液中GS-441524的排泄情况。结果：单次静脉给药15 mg/kg RDV后，GS-441524平均血药峰浓度（Cmax）为2632 ng/mL (SD 862)；到达Cmax （Tmax）时间为1小时（SD 0）；消除半衰期（t1/2）为5.14 h （SD 0.81）。GS-441524出现在积液中（n = 3只猫），治疗后从尿液中消失（n = 6只猫）。对中位GSTC与实现“简单缓解”之间预测关系的评估未能证明有显著相关性。临床意义：本研究支持RDV和GS-441524用于FIP治疗，建议建立人群药代动力学模型以更好地探索GS-441524治疗药物监测的效用。
Pharmacokinetics of GS-441524 following intravenous remdesivir in six cats and results of therapeutic drug monitoring during treatment of feline infectious peritonitis: 22 cases (2021–2024)
Objectives
This study aimed to: (1) characterise the pharmacokinetics of GS-441524 following intravenous (iv) administration of 15 mg/kg remdesivir (RDV) in client-owned cats with feline infectious peritonitis (FIP); (2) document plasma protein binding of GS-441524 in cats; (3) determine whether trough GS-441524 plasma concentrations predict ‘simple remission’ or survival to 18 months; (4) measure GS-441524 concentration in effusions relative to plasma; and (5) qualitatively assess excretion of GS-441524 in urine.
Materials and Methods
Six cats with FIP were administered 15 mg/kg iv RDV. Serial plasma GS-441524 concentrations were measured using high-performance liquid chromatography (HPLC). Twenty-two cats with FIP had trough plasma concentrations monitored over a 12-week treatment period. Simultaneous effusion and plasma GS-441524 concentrations were compared, and urine was assessed for GS-441524 excretion.
Results
The mean peak plasma concentration of GS-441524 (Cmax) after a single 15 mg/kg iv dose of RDV was 2632 ng/mL (SD 862); time to reach Cmax (Tmax) was 1 hour (SD 0); and elimination half-life (t1/2) was 5.14 hours (SD 0.81). GS-441524 was present in effusions (n = 3 cats) and eliminated in urine following treatment (n = 6 cats). Assessment of the predictive relationship between median GSTC and achieving ‘simple remission’ failed to demonstrate a significant correlation.
Clinical Significance
This study supports the use of RDV and GS-441524 for FIP treatment and suggests that population pharmacokinetic modelling is required to better explore the utility of therapeutic drug monitoring of GS-441524.
期刊介绍：
Journal of Small Animal Practice (JSAP) is a monthly peer-reviewed publication integrating clinical research papers and case reports from international sources, covering all aspects of medicine and surgery relating to dogs, cats and other small animals. These papers facilitate the dissemination and implementation of new ideas and techniques relating to clinical veterinary practice, with the ultimate aim of promoting best practice. JSAP publishes high quality original articles, as well as other scientific and educational information. New developments are placed in perspective, encompassing new concepts and peer commentary. The target audience is veterinarians primarily engaged in the practise of small animal medicine and surgery.
In addition to original articles, JSAP will publish invited editorials (relating to a manuscript in the same issue or a topic of current interest), review articles, which provide in-depth discussion of important clinical issues, and other scientific and educational information from around the world.
The final decision on publication of a manuscript rests with the Editorial Board and ultimately with the Editor. All papers, regardless of type, represent the opinion of the authors and not necessarily that of the Editor, the Association or the Publisher.
The Journal of Small Animal Practice is published on behalf of the British Small Animal Veterinary Association and is also the official scientific journal of the World Small Animal Veterinary Association
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
